STOCKS TELEGRAPH

Tag: CLLS

  • Removal of FDA’s Hold on Clinical Trials: Cellectis S.A. (CLLS) stock Soars High Premarket

    On January 10, Cellectis S.A. (CLLS) shared that its licensed partner, Allogene Therapeutics Inc. has announced the removal of the FDA’s hold on its clinical trials. Consequently, the stock was trading at $8.83 per share premarket, at the last check on Tuesday.

    In the previous session, CLLS stock added a value of 2.59% at its close of $7.92 with 234.49K shares exchanging. Following the announcement, the stock had gained a further 11.49% premarket, at the time of writing.

    The clinical-stage biopharmaceutical company, Cellectis S.A. has a market capitalization of $361.75 million. Currently, the company has 45.48 million shares outstanding in the market.

    What Happened?

    On October 07, the FDA appointed a clinical hold on all the ongoing trials of Allogene. The reason for this clinical hold was a chromosomal abnormality report which was detected in a single patient of Allogene’s ALPHA2 study. Moreover, no other patient treated with the same ALLO-501A lot was affected by the abnormality. In addition, it was also not present in any product of AlloCAR TTM. Hence, the investigation resulted in the conclusion that the abnormality had no relation with TALEN® gene editing or Allogene’s manufacturing process. The investigations further concluded that the chromosomal abnormality had no clinical significance.

    Furthermore, the abnormality involved certain regions of T cell receptor and immunoglobulin genes. As part of natural T cell or B cell maturation, these regions usually undergo rearrangement. Hence, the conclusion of the investigations led to the removal of the clinical hold on the trials.

    CLLS and Allogene

    Servier and Allogene are jointly developing ALLO-501 and ALLO-501A under a collaboration agreement. The agreement is based on an exclusive license that Cellectis granted to Servier. The allogeneic CAR-T programs of Allogene are based on CLLS’s technologies.

    As per the collaboration agreement, Allogene has exclusive rights to the products in the U.S., and Servier retains the exclusive rights for the rest of the countries.

    CLLS’s Financial Data

    On November 04, the company declared its financial results for the third quarter of 2021.

    In the third quarter of 2021, CLLS had consolidated revenues and other income of $11 million. This compares to $9 million in the third quarter of 2020.

    The company had a consolidated net loss of $37 million in the third quarter of 2021, against $30 million in Q3 of 2020. Resultantly, the net loss per share was $0.82 and $0.71 in the third quarter of 2021 and 2020 respectively.

  • Cellectis (CLLS) hires HR veteran as Executive Vice President, Chief Human Resources Officer

    Cellectis (Nasdaq: CLLS), a biopharmaceutical firm, today confirmed the appointment of Kyung Nam-Wortman as Chief Human Resources Officer and Executive Vice President of Cellectis. Also joining the Company’s Executive Committee is Ms. Nam-Wortman, who will be based in the New York office of Cellectis.

    Ms. Nam-Wortman will work closely with Dr. Choulika and the executive teams in her new position at Cellectis to ensure that the organization progresses the strategy through the recruiting and retaining of talented people. She will also focus on further cultivating and strengthening the diverse and multicultural community of Cellectis while maximizing the role of the human resource of the organization.

    Ms. Nam-Wortman joins Cellectis from Achillion, where she worked as Senior VP, Head of HR, Head of IT, Facilities, and Internal Communications.  She was responsible for managing the strategic and organizational aspects of the above roles at Achillion.

    Cellectis (Nasdaq: CLLS), a biopharmaceutical firm, today confirmed the appointment of Kyung Nam-Wortman as Chief Human Resources Officer and Executive Vice President of Cellectis. Also joining the Company’s Executive Committee is Ms. Nam-Wortman, who will be based in the New York office of Cellectis.

    Ms. Nam-Wortman will work closely with Dr. Choulika and the executive teams in her new position at Cellectis to ensure that the organisation progresses the strategy through the recruiting and retaining of talented people. She will also focus on further cultivating and strengthening the diverse and multicultural community of Cellectis, while maximising the human resources role of the organisation.

    Kyung Nam-Wortman joins Cellectis from Achillion, where she worked as Senior Vice President, Head of HR, Head of IT, Facilities and Internal Communications.  She was responsible for managing the strategic and organisational aspects of the above roles at Achillion.

    Ms. Nam-Wortman served as VP and Head of Global Talent and Corporate Capacity at Zoetis prior to her time at Achillion, where she helped spin-off of the animal health business unit of Pfizer via its IPO and was key player for standing up the international talent management role of Zoetis to boost the development of the sector worldwide. She has held numerous major positions in HR with Pfizer’s company groups, branches, and domestic and global management functions.

    Ms. Nam-Wortman has 14 years of expertise in the consultancy field focusing on strategic and organisational change management from Delta Consulting Group and IBM, in addition to her success with biotech/biopharma.

    After completing her bachelor’s degree in marketing from the New York University Stern School of Business Ms. Nam-Wortman did her MS in Human Resources Management/Organizational Growth from the New School of Social Research’s

    Cellectis (Nasdaq: CLLS), a biopharmaceutical firm, today confirmed the appointment of Kyung Nam-Wortman as Chief Human Resources Officer and Executive Vice President of Cellectis. Also joining the Company’s Executive Committee is Ms. Nam-Wortman, who will be based in the New York office of Cellectis.

    Ms. Nam-Wortman will work closely with Dr. Choulika and the executive teams in her new position at Cellectis to ensure that the organization progresses the strategy through the recruiting and retaining of talented people. She will also focus on further cultivating and strengthening the diverse and multicultural community of Cellectis while maximizing the role of the human resource of the organization.

    Ms. Nam-Wortman joins Cellectis from Achillion, where she worked as Senior Vice President, Head of HR, Head of IT, Facilities, and Internal Communications.  She was responsible for managing the strategic and organizational aspects of the above roles at Achillion.

    Kyung Nam-Wortman served as VP and Head of Global Talent and Corporate Capacity at Zoetis prior to her time at Achillion, where she helped spin-off of the animal health business unit of Pfizer via its IPO and was a key player for standing up the international talent management role of Zoetis to boost the development of the sector worldwide.

    Ms. Nam-Wortman has 14 years of expertise in the consultancy field focusing on strategic and organizational change management from Delta Consulting Group and IBM, in addition to her success with biotech/biopharma.

    After completing her bachelor’s degree in marketing from the New York University SternSchool of Business Ms. Nam-Wortman did her MS in Human ResourcesManagement/Organizational Growth from the New School of Social Research’s.

    MS. Nam-Wortman served as VP and Head of Global Talent and Corporate Capacity at Zoetis prior to her time at Achillion, where she helped spin-off the animal health business unit of Pfizer via its IPO and was a key player for standing up the international talent management role of Zoetis to boost the development of the sector worldwide. She has held numerous major positions in HR with Pfizer’s company groups, branches, and domestic and global management functions.

    Ms. Nam-Wortman has 14 years of expertise in the consultancy field focusing on strategic and organizational change management from Delta Consulting Group and IBM, in addition to her success with biotech/biopharma.

    After completing her bachelor’s degree in marketing from the New York University Stern School of Business Ms. Nam-Wortman did her MS in Human Resources Management/Organizational Growth from the New School of Social Research’s.